ATAI
safety tolerability efficacy internal product goal differentiation from other therapies with at home unsupervised use objective for this trial sedation and dissociation cadss comparable to placebo as risk ratio of internal product goal rapid and sustained efficacy with week dosing comparable to other therapies objective for this trial improvement in placebo at hours of for a single dose important to note redosing may increase magnitude of effect over time as seen for example in studies in doses may be adjusted in future trials to further optimize the balance of efficacy and tolerability potentially less functional studies due to improved tolerability phase a singe study designed test therapeutic index against severe | ATAI
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
17 of 41
Related slides by other companies
Alkermes
Investor Conference
January 2024
results from full cohort support advancement to phase | Alkermes
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io